Suppr超能文献

口服利福平会干扰肺结核患者的尿液试纸检测。

Oral rifampicin interferes with urine dipstick tests for patients with pulmonary tuberculosis.

作者信息

Wang Fei, Zhao Lihui, Du Wei, Hu Yan, Ren Yi

机构信息

Department of Laboratory Medicine, Wuhan Pulmonary Hospital, Wuhan, China.

Central Medical Laboratory, Wuhan Pulmonary Hospital, Wuhan, China.

出版信息

J Thorac Dis. 2023 May 30;15(5):2636-2643. doi: 10.21037/jtd-23-310. Epub 2023 May 8.

Abstract

BACKGROUND

Rifampicin (RMP) and its major metabolite, desacetyl rifampicin (dRMP), can interfere with urine dipstick tests (UDTs) in patients with tuberculosis (TB) who receive oral RMP. This study sought to examine the effects of RMP and dRMP on UDTs using 2 different urine dipsticks (i.e., Arkray's Aution Sticks 10EA and GIMA's Combi-Screen 11SYS Plus sticks).

METHODS

Urine colorimetry was applied to measure RMP concentrations and determine the range of total RMP concentration in the urine within 2-6 and 12-24 h of oral administration of RMP. In vitro interference assays and confirmatory tests were performed to evaluate the effects of RMP and dRMP on the analytes.

RESULTS

The total RMP concentration in the urine of the 40 TB patients analyzed as urine sample was 88-376 µg/mL within 2-6 h and 22-112 µg/mL within 12-24 h of oral administration of RMP. Interference was observed for different analytes at consistent or varied RMP concentrations between the interference assays and the confirmatory tests, including 75 patients [Aution Sticks 10EA: 250, 250 µg/mL for protein (PRO); 400, 300 µg/mL for leukocyte esterase (LEU); Combi-Screen 11SYS Plus: 125, 150 µg/mL for ketones (KET); 500, 350 µg/mL for nitrite (NIT); 200, 300 µg/mL for PRO; 125, 150 µg/mL for LEU].

CONCLUSIONS

RMP and dRMP interfered with the analytes of the UDTs using the 2 urine dipsticks in different levels. The interference assay is not an ideal substitute for the confirmatory test. The collection of urine samples within 12-24 h of administration of RMP can prevent the interference caused by RMP and dRMP.

摘要

背景

利福平(RMP)及其主要代谢产物去乙酰利福平(dRMP)可干扰接受口服RMP治疗的结核病(TB)患者的尿液试纸条检测(UDT)。本研究旨在使用两种不同的尿液试纸条(即爱科来的Aution Sticks 10EA和吉玛的Combi-Screen 11SYS Plus试纸条)检测RMP和dRMP对UDT的影响。

方法

采用尿比色法测量RMP浓度,并确定口服RMP后2 - 6小时和12 - 24小时内尿液中总RMP浓度范围。进行体外干扰试验和确证试验以评估RMP和dRMP对分析物的影响。

结果

作为尿液样本分析的40例TB患者尿液中,口服RMP后2 - 6小时内总RMP浓度为88 - 376μg/mL,12 - 24小时内为22 - 112μg/mL。在干扰试验和确证试验中,在一致或不同的RMP浓度下观察到不同分析物存在干扰,包括75例患者[Aution Sticks 10EA:蛋白质(PRO)为250、250μg/mL;白细胞酯酶(LEU)为400、300μg/mL;Combi-Screen 11SYS Plus:酮体(KET)为125、

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/055e/10267930/9da37a84cf93/jtd-15-05-2636-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验